ArticleOpen forum infectious diseases2019
The Economic Burden and Impact on Quality of Life of Herpes Zoster and Postherpetic Neuralgia in Individuals Aged 50 Years or Older in Italy.
Article in Open forum infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01772160 (Population Based Surveillance to Estimate the Burden of Herpes Zoster and Post-herpetic Neuralgia in Italy), which is not on this map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Population Based Surveillance to Estimate the Burden of Herpes Zoster and Post-herpetic Neuralgia in Italy
Who cites it
24 citing papers in PubMed, 27 citations in OpenAlex.
- Impact of Reactogenicity After Two Doses of Recombinant Zoster Vaccine Upon Physical Functioning and Quality of Life: An Open Phase III Trial in Older Adults.The journals of gerontology. Series A, Biological sciences and medical sciences · 2021Trial
- Saikosaponin D Attenuates Postherpetic Neuralgia and Reduces Inflammation by Regulating Gut Microbiota in a Rodent Model.Biochemical genetics · 2026Article
- Attitudes of healthcare workers toward recommending vaccination against herpes zoster: a study based on the health belief model and theory of planned behavior.Frontiers in public health · 2026Article
- Spinal Cord Stimulation and DREZ Lesioning for Refractory Postherpetic Neuralgia: An Exploratory Case Series.Journal of pain research · 2026Article
- Development and External Validation of a Nomogram for Predicting Postherpetic Neuralgia Risk in Patients with Herpes Zoster: A Retrospective Cohort Study.Journal of pain research · 2026Article
- Clinical and economic burden of herpes zoster in Mexico: A retrospective medical chart analysis in a private healthcare setting.Human vaccines & immunotherapeutics · 2025Article
- Quality of life in people with herpes zoster: a cross-sectional study in China.Health and quality of life outcomes · 2025Article
- The Economic Burden of Herpes Zoster in Individuals Aged 50 Years or Older and Those With Underlying Conditions in Italy.Open forum infectious diseases · 2025Article
- New Findings on Risk Factors for Postherpetic Neuralgia From 2014 to 2024: A Systematic Review and Meta-Analysis.Journal of pain research · 2025Review
- Impact of twelve immunization-preventable infectious diseases on population health using disability-adjusted life years (DALYs) in Spain.BMC infectious diseases · 2024Article
- Burden of Herpes Zoster Among Patients with Psoriatic Arthritis in the United States.Psoriasis (Auckland, N.Z.) · 2024Article
- Impact of Herpes Zoster and Postherpetic Neuralgia on the Quality of Life in China: A Prospective Study.Clinical, cosmetic and investigational dermatology · 2024Article
- Epidemiology of herpes zoster in National Guard Hospitals in Saudi Arabia: a 6-year retrospective chart review study.Frontiers in public health · 2024Article
- Burden of Herpes Zoster Among Patients with Psoriasis in the United States.Dermatology and therapy · 2023Article
- Early Diagnosis of Herpes Zoster Neuralgia: A Narrative Review.Pain and therapy · 2023Review
- Dual-neuromodulation strategy in pain management of herpes zoster ophthalmicus: retrospective cohort study and literature review.Annals of medicine · 2023Review
- Resting-State Functional Connectivity Analyses: Brain Functional Reorganization in a Rat Model of Postherpetic Neuralgia.Brain sciences · 2022Article
- Patient-reported quality of life in patients suffering from acute herpes zoster-a systematic review with meta-analysis.British journal of pain · 2022Article
- A Systematic Review on Cannabinoids for Neuropathic Pain Administered by Routes Other than Oral or Inhalation.Plants (Basel, Switzerland) · 2022Review
- Antiviral treatment in outpatients with herps zoster in six major areas of China, 2010-2019.Frontiers in public health · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo estimate the health care resource utilization, costs, and impact on quality of life (QoL) of herpes zoster (HZ) and postherpetic neuralgia (PHN) in adults aged ≥50 years in Italy.
methodsThis was a prospective, observational, multicenter, community physician-based surveillance study (NCT01772160) in Italy. Health-related QoL data were collected using the EuroQoL-5 Dimension (EQ-5D) and Zoster Brief Pain Inventory (ZBPI) questionnaires. Both questionnaires were assessed at days 0 (HZ rash onset), 15, 30, 60, and 90 for all patients, and monthly thereafter for patients who developed PHN. Resource utilization was recorded for 3 months post-HZ onset and 9 months for PHN patients. Costs from both payer and societal perspectives were estimated and were composed of direct medical costs (general practitioner/specialist visits, procedures, hospitalizations, medications), work loss by patient/caregiver, and transport costs.
resultsA total of 391 patients with HZ were included, of whom 40 developed PHN. The mean ZBPI worst pain score was 5.7 at day 0, reducing to 2.6 at day 30 and 0.7 by day 90. Patients with PHN had a mean worst pain score of 5.7 at day 90. We estimated an overall disutility associated with HZ of 0.134. The mean cost per HZ patient from a payer/societal perspective was €153/€298, respectively, and the mean cost per HZ patients who developed PHN was €176/€426, respectively.
conclusionsHZ is associated with impaired QoL and substantial health care resource use, highlighting the need for preventive strategies. This could reduce the disease burden for the patient and health care system. CLINICALTRIALSGOV STUDY REGISTRY: NCT01772160.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.